Graft-Versus-Host Disease
Prospective Assessment of Clinical and Biological Factors Determining Outcomes in Patients With Chronic Graft-Versus-Host Disease (GVHD)
NCI-04-C-0281
Print this page
Investigator(s): |
Steven Pavletic, M.D., M.S. Principal Investigator Phone: 301-402-4899 pavletis@mail.nih.gov
|
|
|
|
Bazetta (Zetta) Blacklock, R.N., B.S., B.S.N. Transplant Coordinator Phone: 301-594-2056 Fax: 301-435-6830 bblacklock@mail.nih.gov
|
|
|
|
Primary Eligibility:
- Age 1-75 years
- Life expectancy of greater than 3 months
- Recipient of an allogeneic (related or unrelated donor) stem cell transplant
- Diagnosed with chronic graft-versus-host disease or referred by physician for the evaluation of possible chronic-graft-versus-host disease
Treatment Plan:
- Trial participants will come to the NIH in Bethesda, MD for a comprehensive, multidisciplinary evaluation lasting 4 days
- Participants will have blood testing, organ evaluation, and comprehensive consults with multidisciplinary team members
- Recommendations will be made to participant’s referring physician for GVHD treatment options
Additional Information:
- This trial will be conducted at the NIH Clinical Center in Bethesda, MD. It is open to patients who meet the eligibility requirements, regardless of where they live in the United States.
- There is no charge for medical care received at NIH Clinical Center.
- FAQs about this study - provides information for patients about the trial such as frequency and duration of visits, costs, how to enroll, treatment plan.
- PDQ (Physicians Data Query) - provides additional details about this study for health care providers.
Reviewed: 7/7/08
Updated: 1/16/09